Ricevi le ultime notizie sulle azioni MoonLake con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MLTX

Ultime notizie per

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Dollar General

Markets

CRDO

FERG

MLTX

Tra utili attesi e voci di un deal miliardario, il mercato si muove. Riflettori su retail, tech e una biotech sotto osservazione.

Dollar General, Signet Jewelers e 3 altre azioni da tenere d&#39;occhio oggi

Central,City,Illinois,-,May,2018:,Dollar,General,Sign,Against

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

Press Releases

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Clear Street Launches Healthcare & Biotechnology Equity Research

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Financing

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

CGEM

CRGX

DCTH

ELVN

ERAS

HTGC

IMTX

IPSC

JANX

NUVB

PTGX

YMAB

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Immunovant

Krystal Biotech

Kymera Therapeutics

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

Goldman Sachs

RBC Capital

Wolfe Research

Needham

HC Wainwright & Co.

Comments

MoonLake Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO